Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome
L.O. Tso, Michael Costello, L.E.T. Albuquerque, Régis B Andriolo, Cristiane R Macedo
Abstract
The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied. Metformin reduces hyperinsulinaemia and suppresses the excessive ovarian production of androgens. It is suggested that as a consequence metformin could improve assisted reproductive techniques (ART) outcomes, such as ovarian hyperstimulation syndrome (OHSS), pregnancy, and live birth rates.
Topics & Concepts
Polycystic ovaryMetforminMedicineLive birthOvarian hyperstimulation syndromeIntracytoplasmic sperm injectionGynecologyOvulation inductionAnovulationPregnancy ratePregnancyIn vitro fertilisationInfertilityObstetricsOvulationInternal medicineInsulinInsulin resistanceHormoneBiologyGeneticsOvarian function and disordersReproductive Biology and FertilityAssisted Reproductive Technology and Twin Pregnancy